Fuming Chanyi Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied under model designation FCP-VET-API as a bulk active pharmaceutical ingredient powder for multi-route veterinary formulation. The material is non-sterile and non-depyrogenated unless a parenteral-grade order specification is approved, and it requires further pharmaceutical processing before administration. The powder is released against a certificate of analysis that references pharmacopoeial methods for identity, assay, related substances, residual solvents, elemental impurities, water determination, bulk and tapped density, particle size distribution, and microbial attributes. The intended downstream routes include direct compression, wet and dry granulation, capsule filling, powder blending, premix dilution, oral solution reconstitution, and injectable solution preparation after suitable sterilisation or aseptic handling. Differentiation from technical fumigation-grade or unstandardised feed powders is based on controlled impurity profiles, residual solvent limits, elemental impurity testing, particle-size consistency, and documentation suitable for GMP downstream use under FDA 21 CFR 210/211, VICH GL18(R), and relevant pharmacopoeial general chapters.

Which release specifications define the veterinary API grade?

The release specification framework is not a single fixed set of values for all routes; it is route-dependent. The table below summarises the compendial alignment tests and the acceptance criteria commonly applied to the powder. Actual batch results are stated on the certificate of analysis, and published data for this specific configuration are limited; therefore, the values should be read as alignment criteria rather than process-development outcomes.

For direct compression, the powder is blended with excipients in a bin blender or V-blender. A 50 L V-blender operating at 15 rpm for 10 min with a fill depth of 60% is a representative development scale; blend uniformity is assessed by sampling 10 locations and comparing the active content against the theoretical concentration. Acceptance is typically a coefficient of variation ≤5.0% and a mean assay between 90.0% and 110.0% of target. Bulk density and tapped density are measured by Ph. Eur. 2.9.34; a Hausner ratio below 1.25 indicates free-flowing powder, while a ratio above 1.40 may require a force feeder or glidant. The powder should be passed through a 500 µm sieve before blending to remove agglomerates; if ambient relative humidity exceeds 60%, pre-drying of the active powder or excipient premix is required to prevent weight variation and sticking. Rotary tablet compression is evaluated for ejection force, hardness, friability, and disintegration. Tablet hardness between 5 kp and 8 kp and friability ≤1.0% are common development targets, but actual acceptance limits are product-specific. The finished tablet is tested for weight variation or content uniformity per USP <905>, and dissolution is performed using USP <711> or Ph. Eur. 2.9.3 with a validated medium selected for the active ingredient solubility.

Batch-to-batch variance is controlled through restricted raw material sourcing and validated crystallisation or drying cycles. Particle size may shift with milling screen wear; therefore, milling screens are inspected for wear at scheduled intervals and particle size distribution is trended for every batch. A shift in D90 of more than 10% from the established baseline triggers review of downstream blending and capsule filling parameters. When the powder is transferred from one manufacturing site to another, full analytical and process-equivalence studies are required before the new site is used for commercial supply.

When granulation moisture exceeds 6%, the downstream processing window narrows

Wet granulation of the API with binder solution requires granulation moisture to remain within 2%–5% by weight as a typical processing window. When moisture exceeds 6%, granule growth accelerates and subsequent tablet disintegration time increases; when moisture falls below 2%, binder distribution becomes uneven and tablet hardness declines. The endpoint is monitored by power consumption on a high-shear granulator and by sieve retention after drying. Drying at inlet air temperature below 60°C may be required if the active substance is thermolabile; confirmed forced degradation data should define the actual thermal boundary. Granule D50 is typically maintained between 150 µm and 400 µm, with oversize material removed through 850 µm screening and fines controlled through 75 µm screening. Capsule filling is controlled by setting the dosing disc to the target fill weight and monitoring weight variation at intervals; the API bulk density should not vary by more than 5% between batches to maintain consistent fill depth. Powder sticking to stainless steel contact parts is mitigated by controlling ambient humidity and by using suitable glidants; compatibility with magnesium stearate should be tested because hydrophobic lubricant films can reduce dissolution if mixing is prolonged beyond 5 min.

For powders, granules, and premix presentations, the API is incorporated by stepwise geometric dilution. A 1:100 preblend is prepared first, then diluted to 1:1000 or the final feeding rate. Carrier particle size is matched so that the D50 difference between API and carrier does not exceed 20%; unmatched particle sizes promote segregation during bulk silo discharge. Homogeneity is checked on representative samples using a validated assay; the coefficient of variation should be ≤5.0% for medicated premixes, but the final acceptance criterion is product-specific and may be tighter for low-dose formulations. The premix is then mixed with complete feed at the prescribed inclusion rate; if the powder is supplied in a granular premix form, the granules are sieved through 850 µm and 150 µm screens to limit both oversize particles and fines.

Controlling injectable solution bioburden before sterilising filtration

Injectable use requires a separate control strategy because the bulk API is not sterile. The powder should be dissolved in water for injection or a suitable co-solvent system at controlled temperature, typically 25°C ± 2°C, with gentle agitation. The resulting solution is clarified and tested for bioburden before sterilising filtration. Bioburden control prior to filtration should follow FDA 21 CFR 211.110 and should be monitored to avoid excessive endotoxin loading even when the filter removes microorganisms; filtration does not remove endotoxin. Filter compatibility studies should use at least 0.22 µm PVDF or PES membranes; if the active substance binds to the membrane, pre-saturation or alternative membrane chemistry is required. The solution is passed through a 0.22 µm sterilising-grade membrane filter validated for bacterial retention per ASTM F838-20 or an equivalent compendial method. After filtration, the finished injectable product is tested for sterility per Ph. Eur. 2.6.1 or USP <71>, for bacterial endotoxins per Ph. Eur. 2.6.14 or USP <85>, and for sub-visible particulate matter per Ph. Eur. 2.9.19 or USP <788>. If the active substance cannot withstand terminal sterilisation, aseptic processing under ISO 14644-1 classified areas is required. Terminal sterilisation may be used only where solution stability and container-closure integrity are confirmed.

Veterinary API grade versus technical and feed-grade powders

The same physical appearance can mask substantial differences in release controls. Technical-grade powders used for fumigation or environmental applications are not produced under pharmaceutical GMP and are not tested against pharmacopoeial impurity, residual solvent, or microbial enumeration chapters. Feed-grade powders may be labelled for oral animal use but often have wider assay tolerances, no endotoxin assessment, and limited particle-size control. The veterinary API grade is intended for formulated medicines and carries a certificate of analysis tied to Ph. Eur., USP, and VICH methods. The table below summarises practical differences.

These differences are operationally significant. A feed-grade powder may be adequate for oral premix use in a non-pharmaceutical feed mill, but it should not be substituted into a tablet, capsule, or injectable manufacturing process without revalidation. The veterinary API grade reduces the testing burden at pharmaceutical incoming inspection because its release documentation is structured for GMP downstream use under FDA 21 CFR 211.84. However, incoming identity testing is still required; compendial documentation does not remove the obligation to confirm identity under the receiving site’s own quality system.

Residual solvent risk is particularly relevant for powders that have undergone solvent crystallisation or spray drying. The release documentation should identify the solvents used in the final crystallisation step. Class 1 solvents such as benzene and carbon tetrachloride must be absent, while Class 2 solvents such as methanol, dichloromethane, and toluene are controlled by the permitted daily exposure. The receiving site should compare the batch certificate with VICH GL18(R) limits because oral and injectable routes can have different permitted daily exposures per dose. If the powder is milled after drying, solvent residues are usually reduced, but solvent content should not be used as a surrogate for residual water, because each is measured by a different method: Ph. Eur. 5.4 for solvents and Ph. Eur. 2.5.12 for water.

Incoming material release should include identity testing by infrared spectroscopy or chromatographic retention time against an authenticated reference standard. The receiving site is responsible for verifying compendial method suitability under its own analytical conditions; method transfer may require the supplier to provide reference chromatograms, relative response factors, and forced degradation data. If the route is parenteral, the receiving site should also assess the extractable profile of the primary packaging because the bulk API may have been stored in contact with polyethylene liners before release. These controls are part of pharmaceutical quality system obligations under FDA 21 CFR 211.84 and EudraLex Volume 4, part II, rather than inherent product properties.

Oral solution and syrup preparation should address reconstitution behaviour, pH, and antioxidant or preservative compatibility. The API powder is reconstituted in purified water or a buffered system at 25°C ± 2°C; agitation at 200 rpm is typical until a clear solution is obtained. Solution clarity is checked against a suitable standard, and the solution is filtered through a 10 µm clarifying filter before storage or further dilution. Preservatives should be selected only after antimicrobial effectiveness testing per Ph. Eur. 5.1.3 or USP <51>; preservative efficacy is not inherent to the API. If the solution is intended for multi-dose use, compatibility with rubber closures and the chosen preservative must be confirmed because rubber extractables can increase turbidity. Published data for this specific configuration are limited, so solubility and stability studies should be conducted with the actual dissolution medium and packaging.

Storage and handling boundaries are route-dependent and stability-driven. The powder is packaged in sealed low-density polyethylene liners inside fibre drums; protection from light and moisture is required. Storage should be in a dry area with temperature not exceeding 25°C unless stability data support a wider range. When a liner is opened, the remaining powder should be re-sealed under dry conditions and re-tested for moisture and microbial load before use in parenteral processing. Re-test period assigned by the manufacturer should not be exceeded, and material held beyond that date should not be released without a full re-test. The API is not intended for direct administration; it must be formulated, diluted, or dissolved into the finished dosage form before veterinary use.